Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biodesix, Inc. - Common Stock (NQ:BDSX)

0.2940 +0.0182 (+6.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biodesix, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Proposed Public Offering of Common Stock
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million
From Biodesix, Inc.
Via Business Wire
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Third Quarter 2022 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
From Biodesix, Inc.
Via Business Wire
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions
From Biodesix, Inc.
Via Business Wire
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Preliminary Revenue for Third Quarter 2022
From Biodesix, Inc.
Via Business Wire
Biodesix to Participate in Two Upcoming Investor Conferences in September
From Biodesix, Inc.
Via Business Wire
Biodesix Named a Top 100 Healthcare Technology Company of 2022
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Second Quarter 2022 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Biodesix, Inc.
Via Business Wire
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
From Biodesix, Inc.
Via Business Wire
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Research Agreement with Top US Cancer Center
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at the H.C. Wainwright Global Investment Conference
From Biodesix, Inc.
Via Business Wire
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
From Biodesix, Inc.
Via Business Wire
Biodesix Announces First Quarter 2022 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
From Biodesix, Inc.
Via Business Wire
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights
From Biodesix
Via Business Wire
Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
From Biodesix, Inc.
Via Business Wire
Biodesix CEO Scott Hutton Named to The Healthcare Technology Report’s List of Top 25 Biotech CEOs in 2022
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited)
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Biodesix, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.